Pacific Edge Limited
Pacific Edge Limited
Your view on PEB.AX
Overview
What the company does, where it operates, and who runs it.
About Pacific Edge Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Peter Meintjes
- Headquarters
- Centre for Innovation, Dunedin, OTA, NZ
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Peter Meintjes
- Headquarters
- Centre for Innovation, Dunedin, OTA, NZ
Pacific Edge Limited, a cancer diagnostics firm headquartered in Dunedin, New Zealand, and established in 2001, is dedicated to the research, development, and commercialization of advanced diagnostic and prognostic tools. These innovations are designed for the early identification and ongoing management of various cancers, with the company's activities spanning New Zealand, the United States, Australia, and Singapore. Its operations are divided into distinct Commercial and Research segments. Central to its product offerings is Cxbladder, a suite of genomic urine tests specifically tailored for the detection and clinical management of bladder cancer. The company is actively expanding this portfolio with several new developments: Cxbladder Resolve, which aims to identify patients likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, designed to flag individuals with haematuria who have a low probability of bladder cancer; Cxbladder Detect, enabling the non-invasive discovery of bladder and other urinary tract cancers; and Cxbladder Monitor, a tool for urologists to track bladder cancer recurrence in patients. In addition to its focus on bladder cancer, Pacific Edge is also progressing with Cxcolorectal, a prognostic gene signature intended for patients diagnosed with stage II or stage III colorectal cancers. Furthermore, the company's development pipeline includes products targeting diagnostics for bladder, gastric, colorectal, and endometrial cancers, as well as melanoma.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Pacific Edge Limited, and the rating behind it. PEB.AX last traded at AUD 0.23; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Pacific Edge Limited. Starting points for Pacific Edge Limited: EPS -AUD 0.03, beta 0.84 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Pacific Edge Limited. Pacific Edge Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Pacific Edge Limited. Trailing twelve-month EPS for Pacific Edge Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Pacific Edge Limited. Pacific Edge Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Pacific Edge Limited valued side by side against its closest peers. Pacific Edge Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Pacific Edge Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Pacific Edge Limited executives and directors. Shares of Pacific Edge Limited have traded between AUD 0.09 and AUD 0.27 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Pacific Edge Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Pacific Edge Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Pacific Edge Limited. Coverage tracks Pacific Edge Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.